Gate Square “Creator Certification Incentive Program” — Recruiting Outstanding Creators!
Join now, share quality content, and compete for over $10,000 in monthly rewards.
How to Apply:
1️⃣ Open the App → Tap [Square] at the bottom → Click your [avatar] in the top right.
2️⃣ Tap [Get Certified], submit your application, and wait for approval.
Apply Now: https://www.gate.com/questionnaire/7159
Token rewards, exclusive Gate merch, and traffic exposure await you!
Details: https://www.gate.com/announcements/article/47889
Patrick Vink Takes the Helm at Arch Biopartners Following Leadership Transition
Arch Biopartners Inc. (ARCH) has revealed a significant management reshuffle on Friday, with Patrick Vink stepping into the Chairman role effective January 15, 2025. This move marks the conclusion of Claude Allary’s tenure at the biopharmaceutical firm.
The incoming Chairman brings substantial pharmaceutical industry experience to the position. Prior to joining ARCH, Vink held the Executive Vice President and Chief Operating Officer role at Cubist Pharmaceuticals, Inc., where he oversaw critical operational functions. His career trajectory also includes a tenure at Mylan Inc. (now operating under the Viatris Inc. banner), where he served as Senior Vice President and managed the Global Head of Hospital Business and Biologics division—a position reflecting his deep expertise in hospital distribution channels and biologics commercialization.
This leadership appointment comes as the company continues to navigate the competitive biopharmaceutical landscape. At market close on Thursday, ARCH equity traded at C$1.37 on the TSXV exchange, reflecting investor sentiment ahead of this organizational change.
The transition underscores Arch Biopartners’ commitment to strengthening its executive leadership with industry veterans capable of driving strategic initiatives in an evolving healthcare sector.